Trial ID or NCT#



not recruiting iconNOT RECRUITING


The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in obese patients. Alterated immune response had been reported in obese patients. The goal of current study is to determine the immune response to interferon in obese compared to non-obese chronic hepatitis C in an tissue culture system.

Official Title

Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Ramsey Cheung
Ramsey Cheung
Professor of Medicine (Gastroenterology and Hepatology) at the Palo Alto Veterans Affairs Health Care System

Contact us to find out if this trial is right for you.